Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease – The Gut and Obesity in Asia (GO‐ASIA) Study
Alimentary Pharmacology & Therapeutics2024Vol. 59(6), pp. 774–788
Citations Over TimeTop 10% of 2024 papers
Nipun Verma, Ajay Duseja, Manu Mehta, Arka De, Huapeng Lin, Vincent Wai‐Sun Wong, Grace Lai–Hung Wong, Ruveena Bhavani Rajaram, Wah‐Kheong Chan, Sanjiv Mahadeva, Ming‐Hua Zheng, Wen‐Yue Liu, Sombat Treeprasertsuk, Thaninee Prasoppokakorn, Satoru Kakizaki, Yosuke Seki, Kazunori Kasama, Phunchai Charatcharoenwitthaya, Phalath Sathirawich, Anand V. Kulkarni, Hery Djagat Purnomo, Lubna Kamani, Yeong Yeh Lee, Mung Seong Wong, Eunice Xiang‐Xuan Tan, Dan Yock Young
Abstract
ML with clinical, anthropometric data and simple blood investigations perform better than FIB-4 for ruling out SF in biopsy-proven Asian NAFLD/MASLD patients.
Related Papers
- → Non-alcoholic Fatty liver Disease in Patients with Psoriasis - Therapeutic Implications(2019)23 cited
- → Fatty Liver Index and Lipid Accumulation Product Can Predict Metabolic Syndrome in Subjects without Fatty Liver Disease(2017)30 cited
- → Prevalence of fatty liver in metabolic syndrome(2020)16 cited
- → Does Non-Alcoholic Fatty Liver Disease (NAFLD) Increase Cardiovascular Risk?(2008)17 cited
- Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease(2019)